Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The firm and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The firm has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). The company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.
How did PLLWF's recent EPS compare to expectations?
The most recent EPS for Polarean Imaging Ltd is $, expectations of $.
How did Polarean Imaging Ltd PLLWF's revenue perform in the last quarter?
Polarean Imaging Ltd revenue for the last quarter is $
What is the revenue estimate for Polarean Imaging Ltd?
According to of Wall street analyst, the revenue estimate of Polarean Imaging Ltd range from $ to $
What's the earning quality score for Polarean Imaging Ltd?
Polarean Imaging Ltd has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Polarean Imaging Ltd report earnings?
Polarean Imaging Ltd next earnings report is expected in 2025-12-24
What are Polarean Imaging Ltd's expected earnings?
Polarean Imaging Ltd expected earnings is $, according to wall-street analysts.
Did Polarean Imaging Ltd beat earnings expectations?
Polarean Imaging Ltd recent earnings of $ expectations.